Initial combination therapy with ambrisentan  + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial

In the randomized, double-blind, event-driven AMBITION study, initial combination therapy with ambrisentan and tadalafil was associated with a 50% reduction in risk of clinical failure (first occurrence of all-cause death, hospitalization for worsening pulmonary arterial hypertension [PAH], disease progression, or unsatisfactory long-term clinical response) vs pooled monotherapy. These results were primarily driven by a reduction in PAH-related hospitalization in the combination therapy group, although a significant effect was not observed in a post-hoc analysis of all-cause hospitalization.

Source: The Journal of Heart and Lung Transplantation - November 21, 2018 Category: Transplant Surgery Authors: Jean-Luc Vachi éry, Nazzareno Galiè, Joan Albert Barberá, Adaani E. Frost, Hossein-Ardeschir Ghofrani, Marius M. Hoeper, Vallerie V. McLaughlin, Andrew J. Peacock, Gérald Simonneau, Christiana Blair, Karen L. Miller, Jonathan Langley, Lewis J. Rubin, Tags: ORIGINAL CLINICAL SCIENCE Source Type: research